LVTX•benzinga•
HC Wainwright & Co. Downgrades LAVA Therapeutics to Neutral, Lowers Price Target to $1.5
Summary
No summary available.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on February 27, 2025 by benzinga